治疗瘤血栓中的抗凝药结果:系统性审查
Lama Alfehaid1,2,3, Samaher Alatmi4,5, Bishier Alfadhel1
1Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Frontiers in oncology
|March 11, 2026
概括
针对瘤血栓 (TT) 的常规抗凝药没有明显的益处,并带有出血风险. 针对瘤的治疗是结果的关键,抗凝固药只适用于标准指示,如DVT或PE.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 血栓形成研究研究
背景情况:
- 瘤血栓 (TT) 是血管内瘤延伸,不同于典型的血栓.
- 抗凝固药疗法通常在经验上用于TT,尽管证据有限.
- 本综述评估了抗凝剂在与固体瘤相关的TT的疗效和安全性.
研究的目的:
- 系统地审查关于固体瘤相关TT的抗凝剂的证据.
- 评估抗凝剂对TT反应,复发,生存和出血的影响.
- 确定TT的最佳管理策略.
主要方法:
- 普里斯玛 (2020) 对PubMed,Embase和CENTRAL的系统审查.
- 包括接受抗凝药的成年人,具有与固体瘤相关的TT.
- 使用GRADE和其他工具评估血栓反应,复发,生存和出血.
主要成果:
- 包括8项研究 (3个队列,5个病例报告).
- 单独抗凝药并没有导致TT回归;针对瘤的治疗是至关重要的.
- 抗凝药没有生存益处;增加出血风险,特别是在细胞癌TT.
- 减少复发的证据有限且异质.
结论:
- 对于孤立的TT而言,常规抗凝药缺乏一致的益处.
- 由于常规原因 (例如,PE,DVT) 表示使用抗凝药.
- 针对瘤的治疗是结果的主要驱动因素;需要进行前性研究.
相关概念视频
Venous Thrombosis III: Interprofessional Care
445
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
445
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
591
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
591
Venous Thrombosis IV: Nursing Management
346
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
346
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
406
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
406
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K


